嗜酸粒细胞趋化蛋白-2血清含量对结直肠癌的诊断价值

Abstract
Figure/Table
References (0)
Related Citation (15)

Download: PDF (1015 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To detect the expression of eosinophil chemotactic protein 2 (eotaxin-2) in the serum of patients with colorectal cancer (CRC), and investigate its clinical significance. Methods: A total of 50 CRC patients seeking medical care in the Gastroenterology Department of Affiliated Hospital of Jiangsu University from January 2020 to February 2021 were selected as the CRC group, and 40 healthy subjects in the same period were selected as the healthy controls. The serum eotaxin-2 levels were detected by enzyme-linked immunosorbent assay (ELISA). The association between eotaxin-2 level and the clinicopathological features of CRC was analyzed, and the value of serum eotaxin-2 in the diagnosis of CRC was evaluated by the receiver operating characteristic (ROC) curve. Results: The expression level of serum eotaxin-2 was significantly higher in CRC than that in the healthy controls (Z=-3.93, P<0.01). No significant differences were found among the expression levels of serum eotaxin-2 with respect to the gender, age, lesion location and tumor size (all P>0.05), but was significantly correlated with the lymph-node metastasis, distant metastasis and TNM stage (all P<0.01). The area under the ROC was 0.742 (95% CI: 0.639-0.845, P<0.01). The sensitivity and specificity of serum eotaxin-2 for the diagnosis of CRC were 68.0% and 77.5%, respectively. Conclusion: Serum eotaxin2 level is increased in CRC patients, and may be a candidate biomarker for the CRC diagnosis.

Received: 18 June 2021

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	XU Xiaowei
	DONG Liyang
	ZHENG Tingting
	LIU Jiameng
	ZHANG Shan
	GAO Xuerong
	MAO Chaoming

Cite this article:

XU Xiaowei,DONG Liyang,ZHENG Tingting等. Diagnostic value of serum eotaxin-2 in colorectal cancer patients[J]. Journal of Jiangsu University(Medicine Edition), 2022, 22(1): 54-57.

URL:

http://zzs.ujs.edu.cn/xbyxb/EN/ OR http://zzs.ujs.edu.cn/xbyxb/EN/Y2022/V22/I1/54

［1］Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2021［J］. CA Cancer J Clin, 2021, 71(1): 7-33.

［2］Worm rntoft MB. Review of bloodbased colorectal cancer screening: How far are circulating cellfree DNA methylation markers from clinical implementation?［J］. Clin Colorectal Cancer, 2018, 17(2): e415-e433.

［3］Chang W, Wu L, Cao F, et al. Development of autoantibody signatures as biomarkers for early detection of colorectal carcinoma［J］. Clin Cancer Res, 2011, 17(17): 5715-5724.

［4］Grothey A, Venook AP. Optimizing adjuvant therapy for localized colon cancer and treatment selection in advanced colorectal cancer［J］. J Natl Compr Canc Netw, 2018, 16(5S): 611-615.

［5］Conlon KC, Miljkovic MD, Waldmann TA. Cytokines in the treatment of cancer［J］. J Interferon Cytokine Res, 2019, 39(1): 6-21.

［6］屠强,彭启松,金洁. 白介素7在结直肠癌患者外周血和癌组织中的表达及其临床意义［J］. 江苏大学学报 (医学版), 2016, 26(5): 437-439.

［7］Korbecki J, Kojder K, Simińska D, et al. CC chemokines in a tumor: A review of procancer and anticancer properties of the ligands of receptors CCR1, CCR2, CCR3, and CCR4［J］. Int J Mol Sci, 2020, 21(21): 8412.

［8］Ahmadi Z, Hassanshahi G, Khorramdelazad H, et al. An overlook to the characteristics and roles played by eotaxin network in the pathophysiology of food allergies: allergic asthma and atopic dermatitis［J］. Inflammation, 2016, 39(3): 1253-1267.

［9］Ablin JN, EntinMeer M, Aloush V, et al. Protective effect of eotaxin2 inhibition in adjuvantinduced arthritis［J］. Clin Exp Immunol, 2010, 161(2): 276-283.

［10］Coleman JM, Naik C, Holguin F, et al. Epithelial eotaxin2 and eotaxin3 expression: relation to asthma severity, luminal eosinophilia and age at onset［J］. Thorax, 2012, 67(12): 1061-1066.

［11］Zajkowska M, Mroczko B. Eotaxins and their receptor in colorectal cancer —A literature review［J］. Cancers (Basel), 2020, 12(6): 1383.

［12］Cheadle EJ, Riyad K, Subar D, et al. Eotaxin2 and colorectal cancer: a potential target for immune therapy［J］. Clin Cancer Res, 2007, 13(19): 5719-5728.

［13］Cho H, Lim SJ, Won KY, et al. Eosinophils in colorectal neoplasms associated with expression of CCL11 and CCL24［J］. J Pathol Transl Med, 2016, 50(1): 45-51.

［14］Tang Z, Kang B, Li C, et al. GEPIA2: an enhanced web server for largescale expression profiling and interactive analysis［J］. Nucleic Acids Res, 2019, 47(W1): W556-W560.

［15］Olsen RS, Nijm J, Andersson RE, et al. Circulating inflammatory factors associated with worse longterm prognosis in colorectal cancer［J］. World J Gastroenterol, 2017, 23(34): 6212-6219.

［16］Gong D, Li Z, Ding R, et al. Extensive serum biomarker analysis in patients with nasopharyngeal carcinoma［J］. Cytokine, 2019, 118: 107-114.

［17］Wang C, Wang Y, Hong T, et al. Blocking the autocrine regulatory loop of Gankyrin/STAT3/CCL24/CCR3 impairs the progression and pazopanib resistance of clear cell renal cell carcinoma［J］. Cell Death Dis, 2020, 11(2): 117.